African American Study of Kidney Disease & Hypertension

非裔美国人肾脏疾病研究

• 批准号: 7477023
• 负责人: VELVIE A POGUE
• 金额: $ 2.07万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-29 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7477023
• 关键词: African American; American; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Cessation of life; Clinical; Cohort Studies; Creatinine; Data; Disease Progression; Economics; End stage renal failure; Enrollment; Genetic; Hypertension; Individual; Kidney; Kidney Diseases; Lead; Metoprolol; Observational Study; Outcome; Participant; Pharmaceutical Preparations; Physiological; Process; Renal function; Risk Factors; Serum; Testing; blood pressure regulation; follow-up; hypertension treatment; prevent; prospective

Pdnci_Inl vestl_lator/PDroir_ercat(moLrasFt,irstM, iddleP):O_lUVel,vAienne Hypertensive kidney disease commonly progresses. The primary objective of the AASK (Afdcan American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK tdal tested the effects on kidney function of 3 medications used as initial antihypertensive therapy (ramipdl, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The pdmary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipdl, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the pedod of the AASK tdal). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.

pdnci_inl vestl_lator/pdroir_ercat（Molrasft，irstm，iddlep）：o_luvel，vaienne 高血压肾脏疾病通常会进展。 AASK的主要目标（AFDCAN美国研究 肾脏疾病和高血压）同类研究是为了确定肾功能和风险的过程 患有高血压肾脏疾病的非裔美国人肾脏疾病进展的因素 推荐的降压治疗。次要目标是确定心血管的发生 疾病并评估其危险因素。 AASK队列研究是一项前瞻性，观察性研究，是AASK试验的扩展。 aask tdal 测试了对3种药物的肾功能的影响 氨氯地平）和2级控制血压。在1,094名试验参与者中，约有650至700个人 尚未达到末期肾脏疾病（ESRD）的人可能会参加队列研究。要研究的风险因素 包括环境，遗传，生理和社会经济变量。 PDMARY肾脏结果是一个复合材料 血清肌酐，ESRD或死亡的一倍来定义的临床结果。高血压的药物治疗 从转化酶抑制剂RAMIPDL的血管紧张素开始，向所有参与者提供。以这种方式， 研究直接控制肾脏疾病进展的两个主要决定因素（高血压治疗和使用 肾脏保护，降压药）。队列研究中的最小随访持续时间为5年 （总共9至12年，包括AASK TDAL的踏板）。 最终，来自AASK队列研究的数据应增强我们对风险因素和过程的理解 确定肾脏疾病的进展。这样的结果最终可能会导致新的策略延迟或阻止 ESRD。